{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:09:18Z","timestamp":1770710958077,"version":"3.49.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Chemotherapeutic agents have been associated with cardiotoxicity; thus, they require close monitoring. Several echocardiographic variables have been investigated as early predictors of symptomatic cardiotoxicity in patients undergoing chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>To identify if global longitudinal strain (GLS) is a better predictor of symptomatic cardiotoxicity compared to left ventricular ejection fraction (LVEF) in patients receiving chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>MEDLINE, Scopus, and Cochrane Central Register of Controlled Trials were searched from inception through December 2020. Adults who developed symptomatic cardiotoxicity (New York Heart Association [NYHA] Class III\u2013IV heart failure, cardiac arrest, or cardiac death) after undergoing chemotherapy with pre- and postchemotherapy echocardiographic measures of cardiac function were included. The primary focus was on the prediction of symptomatic cardiotoxicity. Estimates were reported as random effects hazard ratios (HR) with 95% confidence intervals (CI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Four studies met inclusion criteria. The most common malignancy identified in the included studies was breast cancer, and the most common chemotherapeutic agent utilized was anthracyclines. Most studies utilized the Simpson biplane method to measure echocardiographic parameters. Pooled results demonstrated no significant association between LVEF and the prediction of symptomatic cardiotoxicity (HR 1.48; 95% CI, 0.96\u20132.27; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.07). However, 2 studies that analyzed GLS found it to be a strong predictor of symptomatic cardiotoxicity (HR 1.46; 95% CI, 1.34\u20131.58; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001). There was no significant association between symptomatic cardiotoxicity and baseline left ventricular end diastolic volume, end systolic volume, or end diastolic volume index.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>GLS may predict symptomatic cardiotoxicity and be used to monitor patients on chemotherapy for symptomatic cardiac dysfunction. While the pooled results for baseline LVEF identified that it is not a predictor of symptomatic cardiotoxicity, this differs from the findings of the only randomized trial included in this meta-analysis. The data for baseline GLS as a predictor of symptomatic cardiotoxicity is encouraging, but definite evidence that GLS may be superior to LVEF is lacking. Prospective randomized, blinded trials are required to identify if 1 echocardiographic parameter may be superior to the other.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029562","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T15:07:07Z","timestamp":1662649627000},"page":"e29562","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Echocardiographic predictors of symptomatic cardiotoxicity among patients undergoing chemotherapy: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5375-8702","authenticated-orcid":false,"given":"Muhammad Umer","family":"Siddiqui","sequence":"first","affiliation":[{"name":"Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef","family":"Yaacoub","sequence":"additional","affiliation":[{"name":"Internal Medicine, Catholic Medical Center, Manchester, NH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi-Anne","family":"Hanson","sequence":"additional","affiliation":[{"name":"Internal Medicine, Lake Region General Hospital, Laconia, NH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joey","family":"Junarta","sequence":"additional","affiliation":[{"name":"Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed K.","family":"Pasha","sequence":"additional","affiliation":[{"name":"Vascular Medicine, Mayo Clinic Health System, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahek","family":"Shah","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Thomas Jefferson University Hospital, Philadelphia, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3322\/caac.21349","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.echo.2015.02.001","article-title":"Time trends of left ventricular ejection fraction and myocardial deformation indices in a cohort of women with breast cancer treated with anthracyclines, taxanes, and trastuzumab","volume":"28","author":"Tan","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1179546819866445","DOI":"10.1177\/1179546819866445","article-title":"Cancer therapy-related cardiac dysfunction: an overview for the clinician","volume":"13","author":"Perez","year":"2019","journal-title":"Clin Med Insights Cardiol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N Engl J Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1161\/01.CIR.59.3.421","article-title":"Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations","volume":"59","author":"Hammermeister","year":"1979","journal-title":"Circulation"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.echo.2016.02.018","article-title":"Myocardial strain is associated with adverse clinical cardiac events in patients treated with anthracyclines","volume":"29","author":"Ali","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/echo.13087","article-title":"Temporal trends of cardiac chambers function with trastuzumab in human epidermal growth factor receptor II-positive breast cancer patients","volume":"33","author":"Moustafa","year":"2016","journal-title":"Echocardiogr"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/eurheartj\/ehv529","article-title":"Myocardial strain imaging: how useful is it in clinical decision making?","volume":"37","author":"Smiseth","year":"2016","journal-title":"Eur Heart J"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jcu.22333","article-title":"Predictors of incipient dysfunction of all cardiac chambers after treatment of metastatic renal cell carcinoma by tyrosine kinase inhibitors","volume":"44","author":"Moustafa","year":"2016","journal-title":"J Clin Ultrasound"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the cochrane database of systematic reviews","volume":"41","author":"Turner","year":"2012","journal-title":"Int J Epidemiol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/ebmed-2017-110668","article-title":"Rating the certainty in evidence in the absence of a single estimate of effect","volume":"22","author":"Murad","year":"2017","journal-title":"Evid Based Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjcard.2015.04.064","article-title":"Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-Based chemotherapy","volume":"116","author":"Wang","year":"2015","journal-title":"Am J Cardiol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.ejca.2015.05.028","article-title":"Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study","volume":"51","author":"Pivot","year":"2015","journal-title":"Eur J Cancer"},{"key":"R19-20250504","first-page":"977","article-title":"Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines","volume":"16","author":"Mousavi","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R20-20250504","first-page":"13","article-title":"Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers","volume":"1","author":"Mohan","year":"2018","journal-title":"Antib Ther"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"H390","DOI":"10.1152\/ajpheart.00416.2020","article-title":"Deep learning-based automated left ventricular ejection fraction assessment using 2-D echocardiography","volume":"321","author":"Liu","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12947-021-00261-2","article-title":"Artificial intelligence in echocardiography: detection, functional evaluation, and disease diagnosis","volume":"19","author":"Zhou","year":"2021","journal-title":"Cardiovasc Ultrasound"},{"key":"R23-20250504","first-page":"140","article-title":"Global longitudinal strain accuracy for cardiotoxicity prediction in a cohort of breast cancer patients during anthracycline and\/or trastuzumab treatment","volume":"110","author":"Gripp","year":"2018","journal-title":"Arq Bras Cardiol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjcard.2017.12.022","article-title":"Usefulness of Integrating heart failure Risk factors into impairment of global longitudinal strain to predict anthracycline-related cardiac dysfunction","volume":"121","author":"Milks","year":"2018","journal-title":"Am J Cardiol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/echo.13168","article-title":"Left ventricular global longitudinal strain in HER-2 + breast cancer patients treated with anthracyclines and trastuzumab who develop cardiotoxicity is associated with subsequent recovery of left ventricular ejection Fraction","volume":"33","author":"Fei","year":"2016","journal-title":"Echocardiogr"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European Association of cardiovascular imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"issue":"25 Pt A","key":"R27-20250504","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1875-2136(08)71798-4","article-title":"Automated function imaging: a new operator-independent strain method for assessing left ventricular function","volume":"101","author":"Belghitia","year":"2008","journal-title":"Arch Cardiovasc Dis"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/echo.13446","article-title":"Reproducibility and experience dependence of echocardiographic indices of left ventricular function: side-by-side comparison of global longitudinal strain and ejection fraction","volume":"34","author":"Medvedofsky","year":"2017","journal-title":"Echocardiogr"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:13:55Z","timestamp":1746332035000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":30,"journal-issue":{"issue":"28","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029562","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]}}}